Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Daily Top 10 COVID-19 papers



  Free Subscription


1 Arch Virol
1 Clin Infect Dis
2 Indian Pediatr
2 J Virol
2 Lancet
1 MMWR Morb Mortal Wkly Rep
2 N Engl J Med
1 Nat Immunol
2 Pediatr Infect Dis J
1 PLoS Med
2 PLoS One
2 Proc Natl Acad Sci U S A
4 Science
25 Vaccine

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Arch Virol

  1. SHEGU D, Sori T, Tesfaye A, Belay A, et al
    Sequence-based comparison of field and vaccine strains of infectious bursal disease virus in Ethiopia reveals an amino acid mismatch in the immunodominant VP2 protein.
    Arch Virol. 2020 Apr 13. pii: 10.1007/s00705-020-04622.
    PubMed         Abstract available

    Clin Infect Dis

  2. MCATEER J, Yildirim I, Chahroudi A
    The VACCINES Act, Deciphering Vaccine Hesitancy in the Time of COVID19.
    Clin Infect Dis. 2020 Apr 13. pii: 5819529. doi: 10.1093.

    Indian Pediatr

  3. ELLA KM, Mohan VK
    Coronavirus Vaccines: Light at the End of the Tunnel.
    Indian Pediatr. 2020 Apr 15. pii: S097475591600163.
    PubMed         Abstract available

    Measles Immunization: Worth Considering Containment Strategy for SARS-CoV-2 Global Outbreak.
    Indian Pediatr. 2020;57:380.

    J Virol

  5. CHUANG GY, Lai YT, Boyington JC, Cheng C, et al
    Development of a 3Mut-Apex-Stabilized Envelope Trimer that Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses.
    J Virol. 2020 Apr 15. pii: JVI.00074-20. doi: 10.1128/JVI.00074.
    PubMed         Abstract available

  6. RAMSEY NLM, Visciano M, Hunte R, Loh LN, et al
    A single-cycle glycoprotein D deletion viral vaccine candidate, DeltagD-2, elicits polyfunctional antibodies that protect against ocular herpes simplex virus.
    J Virol. 2020 Apr 15. pii: JVI.00335-20. doi: 10.1128/JVI.00335.
    PubMed         Abstract available


  7. CHEN GL, Coates EE, Plummer SH, Carter CA, et al
    Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.
    JAMA. 2020;323:1369-1377.
    PubMed         Abstract available

  8. STAPLEFORD KA, Mulligan MJ
    A New Vaccine for Chikungunya Virus.
    JAMA. 2020;323:1351-1352.

    FLU-v, a Universal Flu Vaccine Candidate, Advances in Trial.
    JAMA. 2020;323:1336.


  10. LANE R
    Sarah Gilbert: carving a path towards a COVID-19 vaccine.
    Lancet. 2020;395:1247.

  11. MEMISH ZA, Perlman S, Van Kerkhove MD, Zumla A, et al
    Middle East respiratory syndrome.
    Lancet. 2020;395:1063-1077.
    PubMed         Abstract available

    MMWR Morb Mortal Wkly Rep

  12. GOODSON JL, Teleb N, Ashmony H, Musa N, et al
    Progress Toward Measles Elimination - Eastern Mediterranean Region, 2013-2019.
    MMWR Morb Mortal Wkly Rep. 2020;69:439-445.
    PubMed         Abstract available

    N Engl J Med

  13. TAIT DR, Van Der Meeren O, Hatherill M
    A Trial of M72/AS01E Vaccine to Prevent Tuberculosis. Reply.
    N Engl J Med. 2020;382:1577.

    A Trial of M72/AS01E Vaccine to Prevent Tuberculosis.
    N Engl J Med. 2020;382:1576-1577.

    Nat Immunol

  15. ROSKIN KM, Jackson KJL, Lee JY, Hoh RA, et al
    Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth.
    Nat Immunol. 2020;21:199-209.
    PubMed         Abstract available

    Pediatr Infect Dis J

  16. SRICHAROENCHAI S, Kerr SJ, Gatechompol S, Hansudewechakul R, et al
    Prevalence of High-risk Nonavalent Vaccine-type Human Papillomavirus Infection Among Unvaccinated, Sexually Active Asian Female Adolescents With and Without Perinatally Acquired HIV Infection.
    Pediatr Infect Dis J. 2020 Apr 8. doi: 10.1097/INF.0000000000002659.
    PubMed         Abstract available

  17. ARORA NK, Das MK, Poluru R, Kashyap NK, et al
    A Prospective Cohort Study on the Safety of Infant Pentavalent (DTwP-HBV-Hib) and Oral Polio Vaccines in Two South Indian Districts.
    Pediatr Infect Dis J. 2020;39:389-396.
    PubMed         Abstract available

    PLoS Med

  18. SUNDSTROM K, Elfstrom KM
    Advances in cervical cancer prevention: Efficacy, effectiveness, elimination?
    PLoS Med. 2020;17:e1003035.
    PubMed         Abstract available

    PLoS One

  19. BAHEMUKA UM, Abaasa A, Seeley J, Byaruhanga M, et al
    Feasibility of establishing an HIV vaccine preparedness cohort in a population of the Uganda Police Force: Lessons learnt from a prospective study.
    PLoS One. 2020;15:e0231640.
    PubMed         Abstract available

  20. LEUKER C, Samartzidis L, Hertwig R, Pleskac TJ, et al
    When money talks: Judging risk and coercion in high-paying clinical trials.
    PLoS One. 2020;15:e0227898.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  21. PAES W, Leonov G, Partridge T, Chikata T, et al
    Contribution of proteasome-catalyzed peptide cis-splicing to viral targeting by CD8(+) T cells in HIV-1 infection.
    Proc Natl Acad Sci U S A. 2019 Nov 20. pii: 1911622116.
    PubMed         Abstract available

  22. NEWMAN JH, Chesson CB, Herzog NL, Bommareddy PK, et al
    Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer.
    Proc Natl Acad Sci U S A. 2020;117:1119-1128.
    PubMed         Abstract available


    Global polio eradication falters in the final stretch.
    Science. 2020;367:14-15.

  24. STARR D
    Fighting words.
    Science. 2020;367:16-19.

  25. WANG J, Li P, Yu Y, Fu Y, et al
    Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity.
    Science. 2020;367.
    PubMed         Abstract available

    G20 leaders must answer to COVID-19.
    Science. 2020;368:111.


  27. TRAN CH, Afriyie DO, Pham TN, Otsu S, et al
    Rabies post-exposure prophylaxis initiation and adherence among patients in Vietnam, 2014-2016.
    Vaccine. 2019 Feb 2. pii: S0264-410X(19)30093.
    PubMed         Abstract available

  28. SREENIVASAN N, Li A, Shiferaw M, Tran CH, et al
    Overview of rabies post-exposure prophylaxis access, procurement and distribution in selected countries in Asia and Africa, 2017-2018.
    Vaccine. 2019 Aug 27. pii: S0264-410X(19)30475.
    PubMed         Abstract available

  29. HAMPSON K, Abela-Ridder B, Bharti O, Knopf L, et al
    Modelling to inform prophylaxis regimens to prevent human rabies.
    Vaccine. 2018 Dec 7. pii: S0264-410X(18)31519.
    PubMed         Abstract available

  30. RATTANAVIPAPONG W, Thavorncharoensap M, Youngkong S, Genuino AJ, et al
    The impact of transmission dynamics of rabies control: Systematic review.
    Vaccine. 2018 Dec 5. pii: S0264-410X(18)31558.
    PubMed         Abstract available

  31. TARANTOLA A, Ly S, Chan M, In S, et al
    Intradermal rabies post-exposure prophylaxis can be abridged with no measurable impact on clinical outcome in Cambodia, 2003-2014.
    Vaccine. 2018 Nov 16. pii: S0264-410X(18)31420.
    PubMed         Abstract available

  32. IVES A, Dieuzy-Labaye I, Abela-Ridder B
    Global characteristics of the rabies biologics market in 2017.
    Vaccine. 2018 Nov 9. pii: S0264-410X(18)31364.
    PubMed         Abstract available

  33. O'BRIEN KL, Nolan T
    The WHO position on rabies immunization - 2018 updates.
    Vaccine. 2018 Oct 17. pii: S0264-410X(18)31366.

  34. LI AJ, Sreenivasan N, Siddiqi UR, Tahmina S, et al
    Descriptive assessment of rabies post-exposure prophylaxis procurement, distribution, monitoring, and reporting in four Asian countries: Bangladesh, Bhutan, Cambodia, and Sri Lanka, 2017-2018.
    Vaccine. 2018 Oct 9. pii: S0264-410X(18)31363.
    PubMed         Abstract available

  35. WANG S, Yang G, Nie J, Yang R, et al
    Recombinant E(rns)-E2 protein vaccine formulated with MF59 and CPG-ODN promotes T cell immunity against bovine viral diarrhea virus infection.
    Vaccine. 2020 Apr 9. pii: S0264-410X(20)30373.
    PubMed         Abstract available

  36. SOLASTIE A, Leino T, Ollgren J
    Success ofrotavirus vaccination in Finland, a register based study measuring impact beyond overall effectiveness.
    Vaccine. 2020;38:3766-3772.
    PubMed         Abstract available

  37. QUIAMBAO BP, Ambas C, Diego S, Bosch Castells V, et al
    Single-visit, 4-site intradermal (ID) rabies vaccination induces robust immune responses 5 years after 1-week, 4-site ID primary post-exposure prophylaxis in the Philippines.
    Vaccine. 2020;38:3740-3746.
    PubMed         Abstract available

  38. MORICONI A, Onnis V, Aggravi M, Parlati C, et al
    A new strategy for preparing a tailored meningococcal ACWY conjugate vaccine for clinical testing.
    Vaccine. 2020 Apr 13. pii: S0264-410X(20)30463.

  39. CROSS JW, Joy M, McGee C, Akinyemi O, et al
    Adverse events of interest vary by influenza vaccine type and brand: Sentinel network study of eight seasons (2010-2018).
    Vaccine. 2020 Apr 13. pii: S0264-410X(20)30402.
    PubMed         Abstract available

  40. STAPLETON JT, Wagner N, Tuetken R, Bellamy AR, et al
    High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: Results of the DMID 10-0076 randomized clinical trial.
    Vaccine. 2020 Apr 12. pii: S0264-410X(20)30459.
    PubMed         Abstract available

  41. JALLOH MF, Wallace AS, Bunnell RE, Carter RJ, et al
    Ebola vaccine? Family first! Evidence from using a brief measure on Ebola vaccine demand in a national household survey during the outbreak in Sierra Leone.
    Vaccine. 2020 Apr 11. pii: S0264-410X(20)30423.
    PubMed         Abstract available

  42. VESIKARI T, Forsten A, Laudat F, Li P, et al
    Long-term antibody persistence after a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in healthy 5-year-old children.
    Vaccine. 2020 Apr 10. pii: S0264-410X(20)30227.
    PubMed         Abstract available

  43. CHANG CY, Cho CY, Lai CC, Lu CY, et al
    Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in healthy subjects aged 3 to 17 years old: A phase III, open label, single-arm study.
    Vaccine. 2020 Apr 10. pii: S0264-410X(20)30437.
    PubMed         Abstract available

  44. TOTTERDELL J, Phillips A, Glover C, Chidwick K, et al
    Safety of live attenuated herpes zoster vaccine in adults 70-79 years: A self-controlled case series analysis using primary care data from Australia's MedicineInsight program.
    Vaccine. 2020 Apr 10. pii: S0264-410X(20)30443.
    PubMed         Abstract available

  45. LI Y, Lin Y, Xin G, Zhou X, et al
    Comparative evaluation of ELPylated virus-like particle vaccine with two commercial PCV2 vaccines by experimental challenge.
    Vaccine. 2020 Apr 10. pii: S0264-410X(20)30460.
    PubMed         Abstract available

  46. TAPIA MD, Doumbia M, Dembele R, Ball K, et al
    Arranging good clinical practices training and trial monitoring for a vaccine efficacy study during a public health emergency of international concern.
    Vaccine. 2020 Apr 10. pii: S0264-410X(20)30359.
    PubMed         Abstract available

  47. JI YS, Park SK, Ryu S
    Whole leukemia cell vaccines: Past progress and future directions.
    Vaccine. 2020 Apr 9. pii: S0264-410X(20)30421.
    PubMed         Abstract available

  48. GARY E, O'Connor M, Chakhtoura M, Tardif V, et al
    Adenosine deaminase-1 enhances germinal center formation and functional antibody responses to HIV-1 Envelope DNA and protein vaccines.
    Vaccine. 2020 Apr 9. pii: S0264-410X(20)30436.
    PubMed         Abstract available

  49. MAURELLI M, Bellinato F, Gisondi P, Girolomoni G, et al
    Persistent localized hypertrichosis in a Caucasian child at sites of DTPa and chickenpox vaccination.
    Vaccine. 2020;38:3808-3809.

  50. DODD C, de Ridder M, Weibel D, Mahaux O, et al
    ADVANCE system testing: Estimating the incidence of adverse events following pertussis vaccination in healthcare databases with incomplete exposure data.
    Vaccine. 2020 Apr 9. pii: S0264-410X(20)30439.
    PubMed         Abstract available

  51. DIB F, le Sage FV, Cohen R, Launay O, et al
    Recommendation of HPV vaccination to boys in France - An unhappy coincidence with the WHO call to pause the implementation of this vaccination in boys.
    Vaccine. 2020 Apr 15. pii: S0264-410X(20)30487.

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.